Celldex Therapeutics, Inc. CLDX
30.15 USD -0.50 (-1.63%)
At closeNov 11, 2026, 4:01 PM EST
30.15 0.00 0.00%
After hours · Nov 11, 4:01 PM ET
30.14 Day range 31.10
22.33 52-week range 45.14
- YTD
- +11.01%
- 1 year
- +23.72%
News
marketbeat.com Celldex Therapeutics Targets 2027 Filing for Barzolvolimab After Phase 3 Results Celldex Therapeutics NASDAQ: CLDX plans to submit a biologics license application for barzolvolimab in 2027, using full 52-week data from its Phase 3 studies in chronic spontaneous urticaria,…
benzinga.com Canaccord Genuity Maintains Buy on Celldex Therapeutics, Raises Price Target to $68 Canaccord Genuity analyst Edward Nash maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and raises the price target from $60 to $68.
benzinga.com Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $61 Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $57 to $61.- benzinga.com Celldex Therapeutics Q3 EPS $(0.96) Beats $(1.02) Estimate Celldex Therapeutics (NASDAQ:CLDX) reported quarterly losses of $(0.96) per share which beat the analyst consensus estimate of $(1.02) by 5.88 percent. This is a 4.95 percent increase over losses of…
globenewswire.com Celldex to Present at Upcoming Investor Conferences HAMPTON, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming investor conferences: The Guggenheim 3rd…- benzinga.com HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $64 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Celldex Therapeutics (NASDAQ:CLDX) with a Buy and maintains $64 price target.
benzinga.com Leerink Partners Maintains Outperform on Celldex Therapeutics, Raises Price Target to $88 Leerink Partners analyst Thomas Smith maintains Celldex Therapeutics (NASDAQ:CLDX) with a Outperform and raises the price target from $70 to $88.
benzinga.com Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $57 Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $50 to $57.
benzinga.com Crude Oil Down Over 1%; Thor Industries Shares Gain After Q4 Results U.S. stocks were mixed: Nasdaq and S&P 500 rose while the Dow fell; communication services gained, financials dropped, and Thor Industries climbed 5%.
benzinga.com Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease Celldex posts positive Phase 3 data for barzolvolimab to treat chronic spontaneous urticaria. The company plans a 2027 FDA submission.
benzinga.com HC Wainwright & Co. Maintains Buy on Celldex Therapeutics, Raises Price Target to $64 HC Wainwright & Co. analyst Joseph Pantginis maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and raises the price target from $42 to $64.
benzinga.com Cantor Fitzgerald Maintains Overweight on Celldex Therapeutics, Raises Price Target to $72 Cantor Fitzgerald analyst Kristen Kluska maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $61 to $72.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Decoy Therapeutics (NASDAQ:DCOY) shares rose 84.0% to $4.71 during Tuesday's pre-market session. The company's market cap stands at $1.6 million. Greenland Mines (NASDAQ:GRML) shares rose…- benzinga.com Celldex Reports Topline Results From The Company’s Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Trials Evaluating Two Doses Of Barzolvolimab In Patients With Chronic Spontaneous Urticaria; Results Showed Rapid, Profound, Sustained Efficacy, Supporting Barzolvolimab’s Potential To Be A Transformational Therapy In CSU EMBARQ-CSU1 and -CSU2 met primary and all key secondary endpoints at 12 weeks across both studies and both dose groupsClinically meaningful and statistically significant benefit demonstrated in…
benzinga.com Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $50 Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $46 to $50.- benzinga.com Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $46 Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $40 to $46.
- benzinga.com Barclays Maintains Overweight on Celldex Therapeutics, Raises Price Target to $53 Barclays analyst Etzer Darout maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $48 to $53.
- benzinga.com Celldex Therapeutics Q2 EPS $(0.94) Beats $(1.07) Estimate, Sales $22.000K Miss $954.444K Estimate Celldex Therapeutics (NASDAQ:CLDX) reported quarterly losses of $(0.94) per share which beat the analyst consensus estimate of $(1.07) by 12.15 percent. This is a 10.59 percent decrease over losses…
- benzinga.com Wells Fargo Maintains Overweight on Celldex Therapeutics, Raises Price Target to $72 Wells Fargo analyst Derek Archila maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $48 to $72.
- benzinga.com Wells Fargo Maintains Overweight on Celldex Therapeutics, Lowers Price Target to $48 Wells Fargo analyst Derek Archila maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and lowers the price target from $54 to $48.
- benzinga.com Morgan Stanley Maintains Overweight on Celldex Therapeutics, Lowers Price Target to $40 Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and lowers the price target from $44 to $40.
benzinga.com Pegasystems Posts Downbeat Q2 Results, Joins Adtran, Dyne Therapeutics And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session Pegasystems Inc (NASDAQ: PEGA) reported lower-than-expected earnings and sales, causing stocks to fall 16% in pre-market trading.
benzinga.com Cantor Fitzgerald Maintains Overweight on Celldex Therapeutics, Lowers Price Target to $61 Cantor Fitzgerald analyst Kristen Kluska maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and lowers the price target from $67 to $61.
benzinga.com Celldex Treatment Fails To Relieve Chronic Itch, Abandons Prurigo Nodularis Study Celldex has discontinued its Phase 2 trial of barzolvolimab for prurigo nodularis after failing to meet primary and secondary endpoints.
benzinga.com Canaccord Genuity Maintains Buy on Celldex Therapeutics, Lowers Price Target to $60 Canaccord Genuity analyst Edward Nash maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and lowers the price target from $62 to $60.- benzinga.com Celldex Reports Topline Results From Phase 2 Study Of Barzolvolimab In Prurigo Nodularis; Study Did Not Meet Key Efficacy Objectives Study did not meet key efficacy objectivesFavorable safety profile consistent with prior studies, including with new 450mg loading dose and up to 300mgQ4W regimenProfound systemic mast cell…
- benzinga.com Guggenheim Maintains Buy on Celldex Therapeutics, Raises Price Target to $100 Guggenheim analyst Yatin Suneja maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and raises the price target from $90 to $100.
- benzinga.com Celldex CFO Sam Martin Plans To Retire In 2027 Celldex (NASDAQ:CLDX) announced today that Sam Martin, Senior Vice President and Chief Financial Officer, has informed the Company of his plans to retire in 2027. Mr. Martin has served as the…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $42 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Celldex Therapeutics (NASDAQ:CLDX) with a Buy and maintains $42 price target.
- benzinga.com Reported Sunday, Celldex Presents Phase 1 CDX-622 Data At EAACI 2026 Showing Bispecific Antibody Targeting Soluble SCF And TSLP Achieves Profound Mast Cell Depletion With Favorable Safety Profile CDX-622 is a novel, bispecific antibody combining mast cell depletion and TSLP inhibition, two independent pathways contributing to multiple I&I diseasesCDX-622 targets the soluble form of stem cell…
- benzinga.com Reported Sunday, Celldex Presents Phase 2 Data Showing Up To 64% Of Barzolvolimab-Treated CSU Patients Remained Angioedema-Free Seven Months After Last Dose At EAACI Annual Meeting Treatment with barzolvolimab resulted in rapid, significant, and durable improvements in angioedema in patients with moderate to severe CSUSeven months after the completion of dosing (Week 76), up to…
- benzinga.com Celldex To Highlight Three Presentations From Barzolvolimab And CDX-622 Programs At EAACI Annual Congress 2026 -- Flash talks on barzolvolimab clinical program in CSU and Cold Urticaria ---- Late-breaking poster presentation on CDX-622 --HAMPTON, N.J., June 10, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX)…
- benzinga.com UBS Maintains Buy on Celldex Therapeutics, Raises Price Target to $45 UBS analyst David Dai maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and raises the price target from $38 to $45.
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session - benzinga.com Wells Fargo Maintains Overweight on Celldex Therapeutics, Raises Price Target to $54 Wells Fargo analyst Derek Archila maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $38 to $54.
- benzinga.com Barclays Maintains Overweight on Celldex Therapeutics, Raises Price Target to $48 Barclays analyst Etzer Darout maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $45 to $48.
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com Celldex Therapeutics Q1 EPS $(1.18) Beats $(1.20) Estimate, Sales $15.000K Miss $972.222K Estimate Celldex Therapeutics (NASDAQ:CLDX) reported quarterly losses of $(1.18) per share which beat the analyst consensus estimate of $(1.20) by 1.67 percent. This is a 45.68 percent decrease over losses of…
- benzinga.com Barclays Upgrades Celldex Therapeutics to Overweight, Raises Price Target to $45 Barclays analyst Etzer Darout upgrades Celldex Therapeutics (NASDAQ:CLDX) from Underweight to Overweight and raises the price target from $24 to $45.
- benzinga.com Celldex Therapeutics Commences Common Stock Offering; Terms Undisclosed Celldex Therapeutics, Inc. ("Celldex" or the "Company") (NASDAQ:CLDX) today announced that it has commenced an underwritten public offering for the sale of shares of its common stock. In addition,…
- benzinga.com Celldex Presents Announces Data From Phase 2 Clinical Studies Of Barzolvolimab In Chronic Spontaneous Urticaria And Cold Urticaria And Symptomatic Dermographism Shows Enhancement In Patient Quality Life Throughout All Measures Domains Celldex (NASDAQ:CLDX) presented additional positive data from the completed Phase 2 clinical trials of barzolvolimab in chronic spontaneous urticaria (CSU) and cold urticaria (ColdU) and symptomatic…
- benzinga.com Goldman Sachs Maintains Neutral on Celldex Therapeutics, Raises Price Target to $34 Goldman Sachs analyst Richard Law maintains Celldex Therapeutics (NASDAQ:CLDX) with a Neutral and raises the price target from $30 to $34.
- benzinga.com Celldex Presents Additional Results From Phase 2 Clinical Sturies Of Barzolvolimab In Chronic Spontaneous Urticaria And Cold Urticaria And Symptomatic Dermographism At 2026 Allergy, Asthma & Immunology's Annual Meeting Celldex (NASDAQ:CLDX) presented additional positive data from the completed Phase 2 clinical trials of barzolvolimab in chronic spontaneous urticaria (CSU) and cold urticaria (ColdU) and symptomatic…
- benzinga.com Stifel Reiterates Buy on Celldex Therapeutics, Raises Price Target to $68 Stifel analyst Alex Thompson reiterates Celldex Therapeutics (NASDAQ:CLDX) with a Buy and raises the price target from $58 to $68.
- benzinga.com Celldex Therapeutics Q4 EPS $(1.22) Misses $(1.00) Estimate, Sales $100.000K Miss $1.477M Estimate Celldex Therapeutics (NASDAQ:CLDX) reported quarterly losses of $(1.22) per share which missed the analyst consensus estimate of $(1.00) by 21.88 percent. This is a 71.83 percent decrease over losses…
- benzinga.com Celldex Completes Enrollment In Global Phase 3 Program Of Barzolvolimab In Chronic Spontaneous Urticaria, Which Consists Of Two Phase 3 Trials, EMBARQ-CSU1 And EMBARQ-CSU2 Enrollment completed six months ahead of guidance, driven by significant unmet need for better treatments in CSUTopline data expected Q4 2026BLA submission planned for 2027HAMPTON, N.J., Feb. 25,…
- benzinga.com Barclays Maintains Underweight on Celldex Therapeutics, Raises Price Target to $24 Barclays analyst Etzer Darout maintains Celldex Therapeutics (NASDAQ:CLDX) with a Underweight and raises the price target from $21 to $24.
benzinga.com Argenx, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session - benzinga.com Celldex Initiates Global Phase 3 Trial To Establish Efficacy And Safety Of Barzolvolimab In Adult Patients With ColdU And SD Who Remain Symptomatic Despite H1 Antihistamine Treatment No advanced therapies approved to treat ColdU and SD—diseases of misery that dramatically impact all aspects of patient lifeBarzolvolimab is the only drug in development to demonstrate clinical…
benzinga.com Tech Rallies, Palantir Jumps 6% As Shutdown End Looms: What's Moving Markets Monday? Wall Street rebounded on Monday, recovering part of last week's steep losses as investors grew more confident about risk assets amid encouraging signs from Washington that the record-long government…